Email this article Clinical case of testicular serous papillary tumor with ovarian stroma
- Authors: Grebenkin E.V.1,2, Koshmelev A.A.3, Monod P.3, Baranova E.O.3, Popov P.A.3, Atayan D.P.3, Pasechnik D.G.1, Pavlov K.A.1,4, Untesco M.5, Shabanova I.E.1, Kryuchkov I.R.1, Shved N.V.1, Zhivov A.V.3
-
Affiliations:
- UNIM
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
- Ilyinskaya Hospital
- State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency
- Telemark Hospital
- Issue: Vol 20, No 1 (2024)
- Pages: 109-115
- Section: CLINICAL NOTES
- Published: 17.05.2024
- URL: https://oncourology.abvpress.ru/oncur/article/view/1704
- DOI: https://doi.org/10.17650/1726-9776-2024-20-1-109-115
- ID: 1704
Cite item
Full Text
Abstract
Serous tumors are rare in the group of non-germ cell testicular tumors, ad are morphologically similar to serous ovarian tumors. Preoperative diagnosis of this tumor is difficult due to the lack of specific signs according to clinical and instrumental research methods. In turn, histological verification of a serous borderline tumor is also a difficult task and requires differential diagnosis, primarily with serous cystadenocarcinoma, which, unlike a serous borderline tumor, can metastasize and is generally characterized by worse prognosis. Immunohistochemical examination allows to exclude other tumors with a similar morphological structure, including mesothelial tumors. Due to the rare occurrence of testicular serous tumors, there is minimal clinical experience in the treatment of these tumors worldwide, and there is still no consensus on guidelines for their treatment. Radical orchiectomy is recommended for patients with border-line serous tumors.
This article presents a clinical case of a testicular serous borderline papillary tumor with a discussion of the literature data on the instrumental, morphological, and immunohistochemical characteristics of this rare tumor in men.
About the authors
E. V. Grebenkin
UNIM; National Research Nuclear University MEPhI (Moscow Engineering Physics Institute)
Author for correspondence.
Email: grebenkin_urolog@mail.ru
ORCID iD: 0000-0002-4990-6722
SPIN-code: 6798-3427
Evgeniy V. Grebenkin.
Build. 1A, 11 Ordzhonikidze St., Moscow 115419; 31 Kashirskoe Shosse, Moscow 115409
Russian FederationA. A. Koshmelev
Ilyinskaya Hospital
Email: koshmelev44@mail.ru
ORCID iD: 0000-0002-7736-6030
SPIN-code: 8918-1875
Build. 2, 2 Rublevskoe Predmest’e St., Glukhovo, Moscow Region 143421
Russian FederationP. Monod
Ilyinskaya Hospital
Email: monod.pierre@wanadoo.fr
ORCID iD: 0009-0002-7074-5115
Monod Pierre Charles Olivier.
Build. 2, 2 Rublevskoe Predmest’e St., Glukhovo, Moscow Region 143421
Russian FederationE. O. Baranova
Ilyinskaya Hospital
Email: ekaterina__baranova@mail.ru
ORCID iD: 0000-0002-3524-801X
SPIN-code: 1245-1005
Build. 2, 2 Rublevskoe Predmest’e St., Glukhovo, Moscow Region 143421
Russian FederationP. A. Popov
Ilyinskaya Hospital
Email: popovpavel@mail.ru
ORCID iD: 0000-0003-3300-7076
SPIN-code: 1245-1005
Build. 2, 2 Rublevskoe Predmest’e St., Glukhovo, Moscow Region 143421
Russian FederationD. P. Atayan
Ilyinskaya Hospital
Email: d.atayan@ihospital.ru
ORCID iD: 0000-0001-9816-3008
SPIN-code: 5378-4961
Build. 2, 2 Rublevskoe Predmest’e St., Glukhovo, Moscow Region 143421
Russian FederationD. G. Pasechnik
UNIM
Email: pasechnik@unim.su
ORCID iD: 0009-0009-6216-2818
SPIN-code: 4316-8782
Build. 1A, 11 Ordzhonikidze St., Moscow 115419
Russian FederationK. A. Pavlov
UNIM; State Scientific Center of the Russian Federation – A.I. Burnazyan Federal Medical Biophysical Center, Federal Medical and Biological Agency
Email: pavlovkos@gmail.com
ORCID iD: 0000-0002-9076-8907
SPIN-code: 8198-7203
Build. 1A, 11 Ordzhonikidze St., Moscow 115419; 23 Marshala Novikova St., Moscow 123098
Russian FederationM. Untesco
Telemark Hospital
Email: muntesco@gmail.com
ORCID iD: 0009-0007-7818-1656
Maxim Untesco - pathologist of Telemark Hospital.
3710 Skien, Ulefossvegen 55
NorwayI. E. Shabanova
UNIM
Email: shabanova.i.e.1996@gmail.com
ORCID iD: 0009-0009-4680-9415
Build. 1A, 11 Ordzhonikidze St., Moscow 115419
Russian FederationI. R. Kryuchkov
UNIM
Email: ivan_kr95@mail.ru
ORCID iD: 0000-0002-7561-2584
Build. 1A, 11 Ordzhonikidze St., Moscow 115419
Russian FederationN. V. Shved
UNIM
Email: shved@unim.su
ORCID iD: 0000-0001-6462-1875
SPIN-code: 3344-2986
Build. 1A, 11 Ordzhonikidze St., Moscow 115419
Russian FederationA. V. Zhivov
Ilyinskaya Hospital
Email: a.zhivov@ihospital.ru
ORCID iD: 0009-0009-6916-6328
SPIN-code: 9152-3750
Build. 2, 2 Rublevskoe Predmest’e St., Glukhovo, Moscow Region 143421
Russian FederationReferences
- WHO Classification of Tumours Editorial Board. Urinary and male genital tumours. WHO Classification of Tumours Series, 5th edn., vol. 8. Lyon (France): International Agency for Research on Cancer, 2022. Available at: https://publications.iarc.fr/610.
- Lin M.S., Ayala A.G., Ro J.Y. Ovarian-type tumors (Mullerian tumors) of the testis: clinicopathologic findings with recent advances. Ann Urol Oncol 2019;2(1):36–45. Available at: https://doi.org/10.32948/auo.2019.03.07
- Aravind S., Nayanar S.K., Varadharajaperumal R. et al. High grade serous cystadenocarcinoma of testis-case report of a rare ovarian epithelial type tumour. J Clin Diagn Res 2017;11(6):ED13–5. doi: 10.7860/JCDR/2017/27743.10097
- Tickoo S.K., Paner G.P., Zhou M. et al. Protocol for the examination of radical orchiectomy specimens from patients with malignant germ cell and sex cord-stromal tumors of the testis. Version: 4.1.0.1.
- Cundell D., Pawade J., Sohail M., Melegh Z. The V600E BRAF mutation in a borderline serous tumour of the testis is genotypic evidence of similarity with its phenotypic ovarian counterpart. Histopathology 2015;67(1):142–4. doi: 10.1111/his.12630
- Algaba F., Mikuz G., Boccon-Gibod L. et al. Pseudoneoplastic lesions of the testis and paratesticular structures. Virchows Arch 2007;451(6):987–97. doi: 10.1007/s00428-007-0502-8
- Gwiti P., Vereczkey I., Cundell D. et al. The mutational frequency of BRAF and KRAS in low-grade serous testicular neoplasms-a case series. Histopathology 2017;71(5):686–92. doi: 10.1111/his.13261
- Hsieh A., Miller M., He W., Shin D. Serous borderline tumor of the testis and associated magnetic resonance imaging findings. Urol Case Rep 2017;14:30–2. doi: 10.1016/j.eucr.2017.06.007
- Cassidy F.H., Ishioka K.M., McMahon C.J. et al. MR imaging of scrotal tumors and pseudotumors. Radiographics 2010;30(3):665–83. doi: 10.1148/rg.303095049
- Bürger T., Schildhaus H.U., Inniger R. et al. Ovarian-type epithelial tumours of the testis: immunohistochemical and molecular analysis of two serous borderline tumours of the testis. Diagn Pathol 2015;10:118. doi: 10.1186/s13000-015-0342-9
- Fonseca D., Manasa P.L., Sharma R., Giridhar A. Borderline serous papillary tumor of the testis. Indian J Pathol Microbiol 2020;63(4):618–9. doi: 10.4103/IJPM.IJPM_837_19
- Mayr D., Hirschmann A., Lohrs U., Diebold J. KRAS and BRAF mutations in ovarian tumors: a comprehensive study of invasive carcinomas, borderline tumors and extraovarian implants. Gynecol Oncol 2006;103(3):883–7. doi: 10.1016/j.ygyno.2006.05.029
- Kurman R.J., Shih I. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. Hum Pathol 2011;42(7):918–31. doi: 10.1016/j.humpath.2011.03.003
- Emmanuel C., Chiew Y.E., George J. et al. Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver. Clin Cancer Res 2014;20(24):6618–30. doi: 10.1158/1078-0432.CCR-14-1292
- Shih I., Kurman R.J. Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004;164(5):1511–8. doi: 10.1016/s0002-9440(10)63708-x
Supplementary files
